

GILEAD SCIENCES INC
Form 8-K
April 03, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

February 18, 2008

Gilead Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-19731

94-3047598

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

333 Lakeside Drive, Foster City, California

94404

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

650-574-3000

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 8.01 Other Events.

On February 18, 2008, Kristen M. Metza, Senior Vice President, Human Resources of Gilead Sciences, Inc., a Delaware corporation (the Company), entered into a stock trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934 (Rule 10b5-1). James M. Denny and Paul Berg, Ph.D., members of the Company's Board of Directors, John C. Martin, Ph.D., President and Chief Executive Officer and a member of the Company's Board of Directors, John F. Milligan, Ph.D., Chief Operating Officer and Chief Financial Officer, Kevin Young, Executive Vice President, Commercial Operations, and Gregg H. Alton, Senior Vice President and General Counsel of the Company, previously established stock trading plans under Rule 10b5-1, and certain other officers and directors of the Company may do so in the future.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Gilead Sciences, Inc.

April 2, 2008

By: /s/ John F. Milligan, Ph.D.

Name: John F. Milligan, Ph.D.

Title: Chief Operating Officer and Chief Financial Officer